共 97 条
[1]
Hicks RJ(2010)Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy Cancer Imaging 10 S83-S91
[2]
Rinke A(2009)Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656-4663
[3]
Muller HH(2011)Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 514-523
[4]
Schade-Brittinger C(2011)Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 501-513
[5]
Klose KJ(2011)First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 268-275
[6]
Barth P(2013)Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours Eur J Nucl Med Mol Imaging 9 388-311
[7]
Wied M(2009)Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network BMC Cancer 38 302-480
[8]
Yao JC(2011)Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours Eur J Nucl Med Mol Imaging 2 472-2423
[9]
Shah MH(2012)Long-term survival, toxicity profile, and role of F-18 FDG PET/CT scan in patients with progressive neuroendocrine tumors following peptide receptor radionuclide therapy with high activity In-111 pentetreotide Theranostics 29 2416-731
[10]
Ito T(2011)Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers J Clin Oncol 20 716-2762